AUTHORS' REPLY

Por Postmus, P E, Smit, E F
Publicado em 1994

New prognostic factors in resectable non-small cell lung cancer.

Por Smit, E F, Groen, H J, Splinter, T A, Ebels, T, Postmus, P E
Publicado em 1996

Acute and cumulative effects of carboplatin on renal function.

Por Sleijfer, D. T., Smit, E. F., Meijer, S., Mulder, N. H., Postmus, P. E.
Publicado em 1989

A phase II study of oral etoposide in elderly patients with small cell lung cancer.

Por Smit, E F, Carney, D N, Harford, P, Sleijfer, D T, Postmus, P E
Publicado em 1989

Validation of [(18)F]FLT as a perfusion-independent imaging biomarker of tumour response in EGFR-mutated NSCLC patients undergoing treatment with an EGFR tyrosine kinase inhibitor

Por Iqbal, R., Kramer, G. M., Frings, V., Smit, E. F., Hoekstra, O. S., Boellaard, R.
Publicado no EJNMMI Res (2018)

Surgical resection for small cell carcinoma of the lung: a retrospective study.

Por Smit, E. F., Groen, H. J., Timens, W., de Boer, W. J., Postmus, P. E.
Publicado em 1994

Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.

Por Bakker, M., Groen, H. J., Smit, E. F., Smeets, J., Riggi, M., Postmus, P. E.
Publicado em 1995

A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.

Por Smit, E. F., Fokkema, E., Biesma, B., Groen, H. J., Snoek, W., Postmus, P. E.
Publicado em 1998

A phase II study of high dose epirubicin in unresectable non small cell lung cancer.

Por Smit, E. F., Berendsen, H. H., Piers, D. A., Smeets, J., Riva, A., Postmus, P. E.
Publicado em 1992

Phase I study of 21 days continuous infusion with vindesine.

Por de Vries, E. G., Smit, E. F., Vendrig, D. E., Holthuis, J. J., Mulder, N. H.
Publicado em 1989

Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy

Por Huisman, C, Biesma, B, Postmus, P E, Giaccone, G, Schramel, F M N H, Smit, E F
Publicado em 2001

Partial-volume correction in dynamic PET-CT: effect on tumor kinetic parameter estimation and validation of simplified metrics

Por Cysouw, M. C. F., Golla, S. V. S., Frings, V., Smit, E. F., Hoekstra, O. S., Kramer, G. M., Boellaard, R.
Publicado no EJNMMI Res (2019)

A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood.

Por Helfrich, W., ten Poele, R., Meersma, G. J., Mulder, N. H., de Vries, E. G., de Leij, L., Smit, E. F.
Publicado em 1997

DNA topoisomerase IIα and -β expression in human ovarian cancer

Por Withoff, S, Zee, A G J van der, Jong, S de, Hollema, H, Smit, E F, Mulder, N H, Vries, E G E de
Publicado em 1999

A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb–IV non-small-cell lung cancer who failed first-line treatment

Por Wachters, F M, Groen, H J M, Biesma, B, Schramel, F M N H, Postmus, P E, Stigt, J A, Smit, E F
Publicado em 2005

VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

Por Kuiper, J L, Lind, J S W, Groen, H J M, Roder, J, Grigorieva, J, Roder, H, Dingemans, A M C, Smit, E F
Publicado em 2012

Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediast...

Por Phernambucq, E C J, Biesma, B, Smit, E F, Paul, M A, Tol, A vd, Schramel, F M, Bolhuis, R J, Postmus, P E
Publicado em 2006

CD133(+) circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients

Por Vroling, L, Lind, J S W, de Haas, R R, Verheul, H M W, van Hinsbergh, V W M, Broxterman, H J, Smit, E F
Publicado em 2010

Oral nutritional supplements containing n-3 polyunsaturated fatty acids affect quality of life and functional status in lung cancer patients during multimodality treatment: an RCT

Por van der Meij, B S, Langius, J A E, Spreeuwenberg, M D, Slootmaker, S M, Paul, M A, Smit, E F, van Leeuwen, P A M
Publicado em 2012

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment

Por Kuiper, J L, Hashemi, S M S, Thunnissen, E, Snijders, P J F, Grünberg, K, Bloemena, E, Sie, D, Postmus, P E, Heideman, D A M, Smit, E F
Publicado no Br J Cancer (2016)